G1-cellcycle Arrest biomarker IGFBP-7 and TIMP-2 as predictors for an Extended postoperative ICU (Intensive Care Unit) stay following vascular surgery at the abdominal aorta

• Conditions: N17.9; Acute renal failure, unspecified

• Registration Number: DRKS00013757
• Lead Sponsor: Klinik für Anästhesiologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-29
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

aortic surgery (via laparotomy or endovascular)

Exclusion Criteria

- not fulfilling the inclusion criteria
- not able to give writen informed consent
- not willing to participate

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
For the prediction of a moderate or severe acute kidney injury blood and urine samples will be collected immediately before and after the surgical procedure, as well as at the first postoperative day. Standard laboratory and G1-cellcycle Arrest biomarker insulin like growth factor binding protein-7” (IGFBP-7) and<br>tissue inhibitor of metalloproteinase-2” (TIMP-2) will be measured. IGFBP-7 and TIMP-2 Levels will be measured by a Point of care device in Urine samples. The standard laboratory markers (e.g. creatinine) will be measured in plasma samples at the central lab (University Hospital Heidelberg).

Secondary Outcome Measures

Name	Time	Method
Association between IGFBP-7xTIMP-2 urine concentrations and the kidney function immediately after the surgical procedure and at the first postoperative day.